



## Recombinant HIV type 2 gp36 [GST] (DAG4739)

This product is for research use only and is not intended for diagnostic use.

### PRODUCT INFORMATION

<b>Product Overview</b>	Recombinant HIV-II coat protein gp36, GST-tagged
<b>Specificity</b>	Immunoreactive with sera of HIV2-infected individuals.
<b>Species</b>	HIV
<b>Purity</b>	> 95%, as determined by SDS-PAGE.
<b>Conjugate</b>	GST
<b>Applications</b>	HIV2 gp36 antigen is suitable for ELISA and Western blots, excellent antigen for detection of HIV with minimal specificity problems.
<b>Format</b>	Lyophilized from 50mM TRIS HCL 8M urea, pH-9.0.
<b>Preservative</b>	None
<b>Storage</b>	This product can be stored in working aliquots at 4° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.

### BACKGROUND

<b>Introduction</b>	HIV-1 and HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears and vaginal fluids. Immunodeficiency develops more slowly with HIV-2. HIV-2 is less infectious in the early stages of the virus than with HIV-1. The infectiousness of HIV-2 increases as the virus progresses. Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection and often some degree of CD4-independence. Despite considerable sequence and phenotypic differences between HIV-1 and 2 envelopes, structurally they are quite similar. Both
---------------------	--

membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal and C-terminal regions of the ectodomain, which is common to many viral and cellular fusion proteins and which seems to drive fusion. HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature (25°C), does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, and is not affected by target membrane glycosphingolipid composition.

---

**Keywords**

Human Immunodeficiency Virus; HIV gp36; HIV; HIV-2 gp36; HIV-2; HIV type 2 gp36

---